Phase I combination study of trabectedin and doxorubicin in patients with soft-tissue sarcoma. - Wikidata - wikimedia - TriplyDB

Phase I combination study of trabectedin and doxorubicin in patients with soft-tissue sarcoma.

Phase I combination study of trabectedin and doxorubicin in patients with soft-tissue sarcoma.

http://www.wikidata.org/entity/Q33381641

about

Advanced soft-tissue sarcoma and treatment options: critical appraisal of trabectedin Trabectedin for Soft Tissue Sarcoma: Current Status and Future Perspectives The value of trabectedin in the treatment of soft tissue sarcoma Trabectedin for advanced soft tissue sarcomas: optimizing use Trabectedin in soft tissue sarcomas Management Strategies in Advanced Uterine Leiomyosarcoma: Focus on Trabectedin Trabectedin for the management of soft-tissue sarcoma.New developments in treatment of ovarian carcinoma: focus on trabectedin Results of a phase I dose escalation study of eltrombopag in patients with advanced soft tissue sarcoma receiving doxorubicin and ifosfamide Combination of trabectedin and gemcitabine for advanced soft tissue sarcomas: results of a phase I dose escalating trial of the German Interdisciplinary Sarcoma Group (GISG).A selective account of effective paradigms and significant outcomes in the discovery of inspirational marine natural products.Trabectedin for metastatic soft tissue sarcoma: a retrospective single center analysis.Trabectedin plus pegylated liposomal doxorubicin in relapsed ovarian cancer: outcomes in the partially platinum-sensitive (platinum-free interval 6-12 months) subpopulation of OVA-301 phase III randomized trial Long-term outcome and effect of maintenance therapy in patients with advanced sarcoma treated with trabectedin: an analysis of 181 patients of the French ATU compassionate use program.Trabectedin: the evidence for its place in therapy in the treatment of soft tissue sarcoma.Trabectedin: safety and efficacy in the treatment of advanced sarcoma Emerging therapies for adult soft tissue sarcoma.A comprehensive safety evaluation of trabectedin and drug-drug interactions of trabectedin-based combinations.Phase I study of the safety and pharmacokinetics of trabectedin with docetaxel in patients with advanced malignancies New medical treatment options and strategies to assess clinical outcome in soft-tissue sarcoma.Trabectedin: an anticancer drug from the sea.Wide-spectrum characterization of trabectedin: biology, clinical activity and future perspectives.Clinical and pharmacokinetic evaluation of trabectedin for the treatment of soft-tissue sarcoma.Treatment of adult soft tissue sarcoma: old concepts, new insights, and potential for drug discovery.Safety evaluation of trabectedin in treatment of soft-tissue sarcomas.Trabectedin: novel insights in the treatment of advanced sarcoma.Going further in the knowledge of Yondelis®; what's new in clinical trials?Treatment of advanced soft tissue sarcoma: efficacy and safety of trabectedin, a multitarget agent, and update on other systemic therapeutic options.Trabectedin and Eribulin: Where Do They Fit in the Management of Soft Tissue Sarcoma?The safety and efficacy of trabectedin for the treatment of liposarcoma or leiomyosarcoma.Efficacy of trabectedin for the treatment of liposarcoma.Current questions in soft tissue sarcoma: further steps with Yondelis®.Metastatic Leiomyosarcoma to the Spine Complicated With Thrombocytopenia.Systemic Therapy in Metastatic or Unresectable Well-Differentiated/Dedifferentiated Liposarcoma.Novel approaches to treatment of leiomyosarcomas.Trabectedin’s contribution to the treatment of sarcomas

P2860

Q26738346-85536A23-1929-4F70-AE6B-250B199F6482 Q26745502-5ADA3246-7135-4152-95CD-DFA3A85443F6 Q26772855-414B68C8-77D5-480F-97EA-DD9ED0AC952E Q26860365-2666EFF8-CED3-4680-9925-9EDD17C2859D Q28085505-1F926E95-E141-45CA-AA87-5935C799ED35 Q28087771-4E638A7A-E111-4383-AE85-7377FF34FB32 Q33384836-4D7FDEB7-FB6A-40C1-A77E-C7746E7334AD Q33393429-F2530A98-1C7E-41FA-8DE7-699CDD078010 Q33406493-3F14B47D-74AC-41F5-8C71-F405F8888870 Q33419792-37310205-C36D-4CE4-9A7B-8C6652C57112 Q33721944-BF0E6C11-EEC3-44CA-866A-68950C12F761 Q34356540-3F59A8A8-AF54-4C98-9A43-871D1A1AA8A5 Q34413664-682533E3-A815-42C5-9F65-39CE97DBA5F6 Q34578850-42121EFD-C150-4D4C-8D7A-7E1AB89093D8 Q34622323-B2E1BB82-9D18-4671-A3A4-17268EC16B9A Q34628607-FFA31015-FAAC-4277-9923-686AFFD94EC9 Q34659806-944513D3-5454-4AF9-9724-010D2D7291C9 Q35246995-B7CC9285-EB4B-4660-892D-51375D9C4ED9 Q37163139-724B765C-6894-4BAD-B304-DAD30EF39B42 Q37577930-7F7BF36E-2CEA-4E71-A5DB-A030F18EEB16 Q37594790-1A82E33B-CDCB-4D97-A65E-6A942BEA5098 Q37760957-EDA4F3A2-DF84-4C8D-AFAD-B61DA4FD43BF Q37969213-33E65CA7-3392-446F-85AE-54D8AD632DAF Q38000323-EE0C1949-11B8-466A-8DC2-5915D557A95D Q38128352-AEB7FCBE-5722-47CB-A1E6-BF38482A065E Q38206396-0AE5B36E-F9FF-49FB-9DA5-71CDC919E6A5 Q38232374-4DFE708D-7885-46E2-8449-866FC13F0541 Q38731757-ED693A97-1142-4680-B293-E4D0E5C04DF4 Q38769613-DDCA5138-AF14-4BCE-9EE1-56DB8FDE439A Q38797843-B0E179EA-82E2-4072-B8C1-83FE19C1E675 Q38951318-9DBAC106-276E-4B3B-9430-73F4CE027915 Q39422853-19A18AAE-A17C-4D52-A2BF-7E9AAA7F42F1 Q47098054-D91A7439-52BF-46F4-BA5E-CCB3D3519F73 Q47144710-CFE1250B-1287-4163-9A6E-4B71BD761952 Q54595774-DCD7A1BF-09A2-4838-AC6A-917ADDE0AFAD Q57570780-5EC038A2-618B-46B8-B52C-DFBE6048AAF0

P2860

Phase I combination study of trabectedin and doxorubicin in patients with soft-tissue sarcoma.

http://www.wikidata.org/entity/Q33381641

description

2008 nî lūn-bûn

@nan

2008 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2008 թվականի հոտեմբերին հրատարակված գիտական հոդված

@hy

2008年の論文

@ja

2008年論文

@yue

2008年論文

@zh-hant

2008年論文

@zh-hk

2008年論文

@zh-mo

2008年論文

@zh-tw

2008年论文

@wuu

name

Phase I combination study of t ...... ents with soft-tissue sarcoma.

@ast

Phase I combination study of t ...... ents with soft-tissue sarcoma.

@en

type

label

Phase I combination study of t ...... ents with soft-tissue sarcoma.

@ast

Phase I combination study of t ...... ents with soft-tissue sarcoma.

@en

prefLabel

Phase I combination study of t ...... ents with soft-tissue sarcoma.

@ast

Phase I combination study of t ...... ents with soft-tissue sarcoma.

@en

P1433

Q33381641-DE5EE289-5A1B-4EE1-8CF6-0C232ABA101A

P1476

Q33381641-73ACFC0A-CAB0-4E08-A4E4-53CB9790646C

P2093

Q33381641-124814D7-2D23-4AC2-AE50-C1C8FB028F83

Q33381641-14C49E7E-FEC2-456C-9C2D-AE8B937596C0

Q33381641-2A151C0D-342F-456A-B81C-7A6EBC8FC06B

Q33381641-34362EF1-283A-489B-AC60-BD4C42094681

Q33381641-9808C222-23A8-4B57-A774-37365FC89266

Q33381641-CBC261BD-5B61-4564-A553-1BF27F55C3F1

P2860

Q33381641-0448CA48-1DFF-4AA6-87F8-2B40C91BA446

Q33381641-0F07EE8D-B650-4C1F-8FE6-E432DD599EFB

Q33381641-106B961E-522B-4796-8330-716B19A884FE

Q33381641-30EE1A66-8412-4058-950A-F10EFAB48324

Q33381641-3FB491A6-4446-49E0-9677-67BFE6C2ACD4

Q33381641-6327969C-C609-44E5-855D-BA4401EE5742

Q33381641-7BFB4CEF-9CAE-48B9-875C-E8503331BBA6

Q33381641-82031FDC-AE1F-4804-90FE-9259761D53C6

Q33381641-84FBB0DC-4ABC-49C9-9CE4-0D6B5092B5AD

Q33381641-875BF7C2-F6B5-4F0A-8144-F29A04C97786

P304

Q33381641-BE4EEF53-2F9F-40A0-BCAE-886893AA113B

P31

Q33381641-3780948D-1A10-4EB1-A1A7-2635400FE2FD

P356

Q33381641-63F5499D-AFEA-40D3-9168-2557EE657930

P407

Q33381641-55218B59-B434-4C77-9BFA-16FBEA952BD7

P433

Q33381641-E736B8A1-572A-440F-A2A2-F1619ED98E8F

P478

Q33381641-25FE3AB3-5AF3-43AC-9B96-042E43C6C1F5

P50

Q33381641-4B7CDB5A-D79C-49C0-A78F-EB3E78ABFC51

Q33381641-A48A73AA-D1F0-4019-8F59-760D3AA960A0

Q33381641-C6CF4432-7720-4B29-9F73-C80439223A5F

Q33381641-DAA83FC8-7DCC-4629-9659-C3CFD32D5215

P577

Q33381641-681A4EBB-0476-4BCF-9B26-59BABFB5D9CF

P698

Q33381641-D1C2BF4B-4C50-45BC-9F34-8C1EB75584D5

P932

Q33381641-9408AB7F-F053-4EA3-B387-FA78A90A3C33

P356

1078-0432.CCR-08-0336

P1433

Clinical Cancer Research

P1476

Phase I combination study of t ...... ents with soft-tissue sarcoma.

@en

P2093

Brian L Samuels

http://www.w3.org/2001/XMLSchema#string

Brigid Buckley

http://www.w3.org/2001/XMLSchema#string

Claudia Lebedinsky

http://www.w3.org/2001/XMLSchema#string

Leen Gilles

http://www.w3.org/2001/XMLSchema#string

Michael P Fanucchi

http://www.w3.org/2001/XMLSchema#string

Yusri A Elsayed

http://www.w3.org/2001/XMLSchema#string

P2860

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

Antiproliferative activity of ecteinascidin 743 is dependent upon transcription-coupled nucleotide-excision repair.

Ecteinascidin-743: a marine-derived compound in advanced, pretreated sarcoma patients--preliminary evidence of activity.

Phase I and pharmacokinetic study of ecteinascidin-743, a new marine compound, administered as a 24-hour continuous infusion in patients with solid tumors.

Phase I and pharmacokinetic study of ecteinascidin 743 administered as a 72-hour continuous intravenous infusion in patients with solid malignancies.

Phase II study of ecteinascidin 743 in heavily pretreated patients with recurrent osteosarcoma.

Doxorubicin versus CYVADIC versus doxorubicin plus ifosfamide in first-line treatment of advanced soft tissue sarcomas: a randomized study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group.

Ecteinascidin 743: a minor groove alkylator that bends DNA toward the major groove.

Phase II study of ecteinascidin-743 in advanced pretreated soft tissue sarcoma patients.

Phase II and pharmacokinetic study of ecteinascidin 743 in patients with progressive sarcomas of soft tissues refractory to chemotherapy.

P304

6656-6662

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1158/1078-0432.CCR-08-0336

http://www.w3.org/2001/XMLSchema#string

P407

P433

20

http://www.w3.org/2001/XMLSchema#string

P478

14

http://www.w3.org/2001/XMLSchema#string

P50

Isabelle Ray-Coquard

Margaret von Mehren

P577

2008-10-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

18927308

http://www.w3.org/2001/XMLSchema#string

P932

2777645

http://www.w3.org/2001/XMLSchema#string